Johnson & Johnson (JNJ) Holdings Increased by Sigma Investment Counselors Inc.

Sigma Investment Counselors Inc. boosted its position in Johnson & Johnson (NYSE:JNJ) by 8.9% during the 1st quarter, HoldingsChannel reports. The firm owned 8,530 shares of the company’s stock after purchasing an additional 695 shares during the quarter. Sigma Investment Counselors Inc.’s holdings in Johnson & Johnson were worth $1,093,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Goodman Financial Corp purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $104,000. Stelac Advisory Services LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $108,000. Price Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $148,000. Roble Belko & Company Inc raised its position in shares of Johnson & Johnson by 59.7% during the 4th quarter. Roble Belko & Company Inc now owns 1,164 shares of the company’s stock valued at $163,000 after buying an additional 435 shares in the last quarter. Finally, Smart Portfolios LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at $150,000. Institutional investors and hedge funds own 65.97% of the company’s stock.

JNJ has been the topic of several research reports. TheStreet cut shares of Johnson & Johnson from an “a” rating to a “c+” rating in a research report on Monday, March 26th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $145.00 target price on the stock in a research report on Wednesday, April 11th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $148.00 to $143.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 10th. Citigroup decreased their target price on shares of Johnson & Johnson from $146.00 to $134.00 and set a “neutral” rating on the stock in a research report on Monday, April 23rd. Finally, Jefferies Financial Group set a $161.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, March 23rd. Six research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $141.60.

Shares of Johnson & Johnson opened at $121.34 on Friday, MarketBeat Ratings reports. The firm has a market capitalization of $325.54 billion, a price-to-earnings ratio of 16.11, a PEG ratio of 1.86 and a beta of 0.73. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.32. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.25 and a current ratio of 1.58.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06. The business had revenue of $20.01 billion for the quarter, compared to analyst estimates of $19.50 billion. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The company’s revenue was up 12.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.83 EPS. research analysts expect that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 12th. Shareholders of record on Tuesday, May 29th were issued a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date was Friday, May 25th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.84. Johnson & Johnson’s dividend payout ratio (DPR) is 49.32%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply